Intended Audience: All neonatal nurses
NCC Codes: NIC2, NNP2, LRN3

Objectives: Upon completion, learners will be able to:

Characterize the risk/benefit profile of pharmacological and non-pharmacological management of the PDA among extremely preterm infants.

Purpose of this CNE activity: Our speakers discuss evidence-base interventions for available pharmacological and non-pharmacological treatments of the patent ductus arteriosus among extremely preterm infants.

Requirements for Completion: The following requirements are necessary for successful completion of this CNE activity.

Access to the internet and the ANN Online Library
Attend and watch 90% of the session
Complete and submit the evaluation for this CNE activity

Accreditation
The Academy of Neonatal Nursing is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Provider, Academy of Neonatal Nursing, approved by the California Board of Registered Nursing, Provider #CEP 6261; and Florida Board of Nursing, Provider #FBN 3218, content code 2505.

Release Date: 9/10/2021
Expiration Date: 9/30/2024

Disclosures:

This CNE activity has been reviewed by the Lead Nurse Planner. It has been determined that the material presented here shows no bias.
The content of this CNE activity has been developed by the planning committee and has been reviewed by the Lead Nurse Planner.
The speaker discloses no relevant financial interest or affiliations with any commercial interests.

Disclaimer: The Academy of Neonatal Nursing assumes no responsibility or liability for the content presented. Care of the infant should always be individualized and no one source relied upon for information regarding aspects of care. Accredited status does not imply endorsement by ANN, ANA, or the American Nurses Credentialing Center of any commercial products displayed or discussed in conjunction with an educational activity.

Credits Available